Challenging interpretation of germline TP53 variants based on the experience of a national comprehensive cancer centre
暂无分享,去创建一个
H. Butz | J. Papp | A. Bozsik | Erika Szőcs | V. Grolmusz | Attila Patócs
[1] William J. R. Longabaugh,et al. The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute , 2022, Cell Death & Differentiation.
[2] A. Patócs,et al. Case Report: A Novel Pathomechanism in PEComa by the Loss of Heterozygosity of TP53 , 2022, Frontiers in Oncology.
[3] A. Patócs,et al. Reclassification of Five BRCA1/2 Variants with Unknown Significance Using Complex Functional Study , 2022, Cancer research and treatment.
[4] S. Savage,et al. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. , 2021, The Lancet. Oncology.
[5] P. Hainaut,et al. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set , 2021, JAMA oncology.
[6] D. Evans,et al. TP53, a gene for colorectal cancer predisposition in the absence of Li-Fraumeni-associated phenotypes , 2020, Gut.
[7] A. Spurdle,et al. Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testing. , 2020, Cancer genetics.
[8] E. Schröck,et al. Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes , 2020, European Journal of Human Genetics.
[9] A. Spurdle,et al. Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants , 2020, medRxiv.
[10] P. Ashton-Prolla,et al. TP53 variants of uncertain significance: increasing challenges in variant interpretation and genetic counseling , 2019, Familial Cancer.
[11] T. Soussi,et al. High prevalence of cancer‐associated TP53 variants in the gnomAD database: A word of caution concerning the use of variant filtering , 2019, Human mutation.
[12] P. Hainaut,et al. Variable population prevalence estimates of germline TP53 variants: A gnomAD‐based analysis , 2018, Human mutation.
[13] Marina T. DiStefano,et al. Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion , 2018, Human mutation.
[14] R. Gelman,et al. Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing , 2018, Journal of the National Cancer Institute.
[15] Alexandros Kouris,et al. VarSome: the human genomic variant search engine , 2018, bioRxiv.
[16] Sarah E. Brnich,et al. Navigating the nuances of clinical sequence variant interpretation in Mendelian disease , 2018, Genetics in Medicine.
[17] Cristina Has,et al. Faculty of 1000 evaluation for Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. , 2018 .
[18] Keith Nykamp,et al. Sources of discordance among germ-line variant classifications in ClinVar , 2017, Genetics in Medicine.
[19] Soma Das,et al. Clinical Laboratories Collaborate to Resolve Differences in Variant Interpretations Submitted to ClinVar , 2017, Genetics in Medicine.
[20] Quan Li,et al. InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. , 2017, American journal of human genetics.
[21] J. Olson,et al. Variability in assigning pathogenicity to incidental findings: insights from LDLR sequence linked to the electronic health record in 1013 individuals , 2017, European Journal of Human Genetics.
[22] Ricardo Villamarín-Salomón,et al. ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..
[23] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[24] H. Meijers-Heijboer,et al. TP53 germline mutation testing in 180 families suspected of Li–Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes , 2010, Journal of Medical Genetics.
[25] Catherine Bonaïti-Pellié,et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] S. Sommer,et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] C. Bonaïti‐pellié,et al. Molecular basis of the Li–Fraumeni syndrome: an update from the French LFS families , 2008, Journal of Medical Genetics.
[28] R. Audisio,et al. Bridging The Age Gap: observational cohort study of effects of chemotherapy and trastuzumab on recurrence, survival and quality of life in older women with early breast cancer , 2021, British Journal of Cancer.